Your session is about to expire
← Back to Search
Amino Acid
Acetyl-L-Carnitine for Friedreich Ataxia
N/A
Waitlist Available
Led By Theresa A Zesiewicz, MD
Research Sponsored by University of South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial is testing if a supplement called ALCAR can help people with Friedreich's Ataxia, a condition that affects movement and the heart. The supplement might help their cells make energy better, which could improve heart function and reduce other symptoms. ALCAR has been shown to improve how cells produce energy in various conditions, including aging and heart issues.
Eligible Conditions
- Friedreich Ataxia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
1Treatment groups
Experimental Treatment
Group I: Acetyl-L-CarnitineExperimental Treatment1 Intervention
Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylcarnitine
FDA approved
Find a Location
Who is running the clinical trial?
University of South FloridaLead Sponsor
424 Previous Clinical Trials
189,862 Total Patients Enrolled
3 Trials studying Friedreich Ataxia
62 Patients Enrolled for Friedreich Ataxia
Theresa A Zesiewicz, MDPrincipal InvestigatorUniversity of South Florida
5 Previous Clinical Trials
33 Total Patients Enrolled
1 Trials studying Friedreich Ataxia
4 Patients Enrolled for Friedreich Ataxia
Share this study with friends
Copy Link
Messenger